GSK completes buyout of Novartis from joint venture
07-06-2018
Novartis, FTC agreement paves way for $16bn buyout of GSK’s cancer unit
24-02-2015
in-focus / iStockphoto.com
Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
GSK, Pfizer, consumer health, joint venture, over the counter products, collaboration, research and development, Advil, Voltaren
